Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Ohio › Columbus
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Columbus, OH keessatti
Qorannoo 35 Leukemia Myeloidii Hamaa f Columbus fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Ohio State University Comprehensive Cancer Center, Columbus
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Ohio State University Comprehensive Cancer Center, Columbus
Ivosidenib as Post-HSCT Maintenance for AML
Namoota walitti qabaa jiraSadarkaa 2
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- fi 8 dabalataa
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Ohio State University Comprehensive Cancer Center, Columbus
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Ohio State University Comprehensive Cancer Center, Columbus
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Nationwide Children's Hospital, Columbus
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Namoota walitti qabaa jiraSadarkaa 1/2
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Namoota walitti qabaa jiraSadarkaa 1
- Ohio State University, The James Comprehensive Cancer, Columbus
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 1/2
- The Ohio Sate University, Columbus
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Namoota walitti qabaa jiraSadarkaa 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Namoota walitti qabaa jiraSadarkaa 3
- US-Colombus OH-OSU, Columbus
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Namoota walitti qabaa jiraQorannoo ilaalaa
- OhioHealth Research Institute, Columbus
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- US-Colombus OH-OSU, Columbus
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Namoota walitti qabaa jiraSadarkaa 2
- Ohio State University Comprehensive Cancer Center, Columbus
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Namoota walitti qabaa jiraSadarkaa 1
- Ohio State University, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Nationwide Children's Hospital, Columbus
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Namoota walitti qabaa jiraSadarkaa 1
- Ohio State University Comprehensive Cancer Center, Columbus
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- Nationwide Children's Hospital, Columbus
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Namoota walitti qabaa jiraSadarkaa 3
- Ohio State University, Columbus
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Nationwide Children's Hospital, Columbus
- The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Namoota walitti qabaa jiraSadarkaa 2
- Ohio State University Comprehensive Cancer Center, Columbus
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- The Ohio State University, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Namoota walitti qabaa jiraSadarkaa 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Ziftomenib Maintenance Post Allo-HCT
Namoota walitti qabaa jiraSadarkaa 1
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Namoota walitti qabaa jiraSadarkaa 1
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
Namoota walitti qabaa jiraQorannoo ilaalaa
- The Ohio State University Medical Center, Columbus
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1/2
- The Ohio State University Wexner Medical Center, Columbus
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Ohio State University, Columbus
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Namoota walitti qabaa jiraSadarkaa 1/2
- Nationwide Children's Hospital, Columbus
Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti
- Houston, TXQorannoo 85
- New York City, NYQorannoo 51
- Boston, MAQorannoo 44
- Seattle, WAQorannoo 41
- Baldwin Park, CAQorannoo 40
- Philadelphia, PAQorannoo 34
- Durham, NCQorannoo 33
- Atlanta, GAQorannoo 31
- Tampa, FLQorannoo 29
- Chicago, ILQorannoo 26
- Portland, ORQorannoo 25
- Washington, DCQorannoo 24
Qorannoo biroo Columbus keessatti
- Kansara Qara'a Non-Small CellQorannoo 57
- Saree OljooQorannoo 40
- Kansarii OvariiQorannoo 39
- Saree (Gosoota Hunda)Qorannoo 38
- Dhibee QaraQorannoo 37
- Luukemiya Limfoositiikii KeessummaaQorannoo 28
- Kansara MetastatikiiQorannoo 27
- Kansa EndometiriyaaliiQorannoo 25
- Kansarii ProstateQorannoo 24
- Myeloma Baay’eeQorannoo 24
- Kansarii ColorectalQorannoo 24
- MelanomaQorannoo 21
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.